FDA-approved1,2Evidence: Large human trialsCancer

Carfilzomib1

Also called Kyprolis1,2

Key takeaway

Carfilzomib is a tetrapeptide epoxyketone, a modified chain of four amino acids, that blocks the proteasome, the cell’s protein-recycling machine. It is the active ingredient in Kyprolis.1,2 FDA approved Kyprolis in 2012. Its label covers relapsed or refractory multiple myeloma, alone or combined with other myeloma drugs.1,2 In the randomized ENDEAVOR trial of 929 people, median progression-free survival was 18.7 months with carfilzomib and dexamethasone versus 9.4 months with bortezomib and dexamethasone. The label has no boxed warning but warns of heart, kidney and lung toxicity.1

Carfilzomib at a glance

What it isA tetrapeptide epoxyketone proteasome inhibitor with the formula C40H57N5O7, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Kyprolis, NDA 202714, with an original approval date of July 20, 2012. The label has no boxed warning.1,2
Human evidenceSeveral randomized, open-label phase 3 trials in relapsed or refractory multiple myeloma described in the label, including ASPIRE (792 people) and ENDEAVOR (929 people).1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is carfilzomib?

Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor, according to the label, which gives its molecular formula as C40H57N5O7.1

In the United States it is the active ingredient of Kyprolis, approved under NDA 202714, according to Drugs@FDA.2

How does carfilzomib work?

The label states that it binds irreversibly to the active sites of the 20S proteasome, the core of the cell’s protein-degrading complex, and that it slowed growth and triggered death of tumour cells in laboratory studies.1

What do human studies show?

In ASPIRE, 792 people with relapsed or refractory multiple myeloma were randomized to carfilzomib with lenalidomide and dexamethasone or to lenalidomide and dexamethasone alone; median progression-free survival was 26.3 versus 17.6 months, and overall survival was also longer with carfilzomib, according to the label.1

In ENDEAVOR, 929 people were randomized to carfilzomib and dexamethasone or bortezomib and dexamethasone; median progression-free survival was 18.7 versus 9.4 months.1

What the evidence base contains

  • Large randomized human trial ASPIRE (NCT01080391): a randomized, open-label trial in 792 people with relapsed or refractory multiple myeloma, in which median progression-free survival was 26.3 months with carfilzomib, lenalidomide and dexamethasone versus 17.6 months without carfilzomib, described in the label.1
  • Large randomized human trial ENDEAVOR (NCT01568866): a randomized, open-label trial in 929 people with relapsed or refractory multiple myeloma comparing carfilzomib with bortezomib, each with dexamethasone, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is carfilzomib FDA-approved?

Yes. Drugs@FDA lists Kyprolis, NDA 202714, with an original approval date of July 20, 2012.2

The Kyprolis label cited here (DailyMed SPL version 59, published June 26, 2025) states that it is indicated for adults with relapsed or refractory multiple myeloma who have had one to three lines of therapy, in combination with other myeloma drugs, and on its own after one or more lines of therapy.1

The label has no boxed warning. It warns of heart failure and other cardiac toxicities, acute kidney failure, tumour lysis syndrome, lung toxicity, pulmonary hypertension and shortness of breath, among other risks.1

Timeline

  1. FDA approves Kyprolis, NDA 202714, according to Drugs@FDA.2
  2. DailyMed publishes version 59 of the Kyprolis label, the version cited here.1

What is still unknown?

Its use outside relapsed or refractory multiple myeloma, which its approved indication does not cover.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Carfilzomib: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Carfilzomib are a bounded selection, not every registration or paper about Carfilzomib. For the years before Carfilzomib was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Carfilzomib as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Carfilzomib in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Kyprolis for relapsed or refractory multiple myeloma. Approval rests on randomized trials including ASPIRE (792 people) and ENDEAVOR (929 people), which found longer progression-free survival. The label has no boxed warning.↗↗

Status sources checked through November 16, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Carfilzomib?

FDA-approved as Kyprolis for relapsed or refractory multiple myeloma. Approval rests on randomized trials including ASPIRE (792 people) and ENDEAVOR (929 people), which found longer progression-free survival. The label has no boxed warning.↗↗

The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
10
Drugs@FDA applications
6

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 16, 2026

ClinicalTrials.gov record NCT07715903↗Added to PeptideScanner November 17, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Carfilzomib?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

62Selected dated records
64Connected citations
10Populated source years2012–2026
3/4Record lanes present

Registered human studies

Trial composition

29 of 29 selected trial records include at least one phase value; 29 of 29 include a status value in the retained structured contract.

PhasesPhase 2 15Phase 3 11Phase 1 3Phase 4 2
Status at observationCompleted 19Active, not recruiting 7Recruiting 2Not yet recruiting 1

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Research Support, Non-U.S. Gov't 13Clinical Trial, Phase II 11Randomized Controlled Trial 9Clinical Trial, Phase III 8Multicenter Study 6Clinical Trial, Phase I 5Review 2Clinical Trial 1Equivalence Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
6
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
62

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 62 dated records

Research hub

Explore the Carfilzomib evidence record

Open all 62 records →
62Dated records
3Evidence types
62Cited public sources
10Source years

Change ledger

Recently changed for Carfilzomib

Open all 62 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03606577

PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06152575

PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07555938

PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.

PeptideScanner change date
November 17, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Carfilzomib

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.Blood advances · 2026 May 12
  2. Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.Nature medicine · 2026 04 06
  3. Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.International journal of hematology · 2025 10 24
Explore all selected literature →
ClinicalTrials.gov29

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07715903Registry update November 16, 2026 · current at observation
  2. NCT03606577Registry update November 12, 2026 · current at observation
  3. NCT06152575Registry update November 12, 2026 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA6

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA209526Full FDA chronology · original submission status AP 2026-07-20
  2. ANDA209330Full FDA chronology · original submission status AP 2021-06-11
  3. ANDA211185Full FDA chronology · original submission status AP 2020-03-20
  4. ANDA209425Full FDA chronology · original submission status AP 2020-03-16
  5. ANDA209422Full FDA chronology · original submission status AP 2019-09-09
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Carfilzomib →

Evidence types

Coverage by source year

Selected records span April 27, 2012 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
Dated updates connected to this profile · 62

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07715903↗

    PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  2. Literature metadata

    Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.↗

    PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03606577↗

    PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06152575↗

    PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07555938↗

    PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  6. Literature metadata

    Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…↗

    PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05497804↗

    PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  8. Literature metadata

    Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.↗

    PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.↗

    PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT04430894↗

    PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT04925193↗

    PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT01559935↗

    PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    KYPROLIS (carfilzomib) for injection · SPL version 59 · published 2025-06-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: KYPROLIS (carfilzomib), NDA 202714 · original approval July 20, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026